◎ Sugi Atlas

Atlas / Drug / Olaparib

Olaparib

drug
On this page

Also known as AZ-2281AZ2281AZD-2281AZD2281KU-0059436KU-59436LynparzaNSC-747856OLAPARIB COMPONENT OF KEYLYNK-010KU0059436OLAPARIB (AZD2281)AZD 2281SID124947876SID174007124SID164339421OlaparibÊOlaparibÂOLAPARIBOLAPARIB

Summary

Olaparib (CHEMBL521686) is an approved small-molecule antineoplastic agent (ATC L01XK01) targeting PARP1, PARP2, and PARP3; indicated across 77 conditions including neoplasm and ovarian carcinoma; with CIViC clinical evidence for 91 variant-indication associations (e.g. BRCA1 Mutation in prostate cancer).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: L01XK01
  • Targets: 3 (PARP1, PARP2, PARP3)
  • Indications: 77 conditions
  • Clinical trials: 383
  • Precision-oncology evidence (CIViC): 91 variant–indication associations
  • Chemistry: 434.5 Da · C24H23FN4O3

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL521686
NameOlaparib
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID23725625
ChEBICHEBI:83766
ATCL01XK01
Molecular formulaC24H23FN4O3
Molecular weight434.5
InChIKeyFDLYAMZZIXQODN-UHFFFAOYSA-N

SMILES: C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F

IUPAC name: 4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one

ChEBI definition: A member of the class of N-acylpiperazines obtained by formal condensation of the carboxy group of 2-fluoro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]benzoic acid with the free amino group of N-(cyclpropylcarbonyl)piperazine; used to treat advanced ovarian cancer.

Pharmacological roles (ChEBI): antineoplastic agent, EC 2.4.2.30 (NAD+ ADP-ribosyltransferase) inhibitor, apoptosis inducer.

Also known as: AZ-2281, AZ2281, AZD-2281, AZD2281, KU-0059436, KU-59436, Lynparza, NSC-747856, Olaparib, OLAPARIB COMPONENT OF KEYLYNK-010, OLAPARIB, KU0059436

Patent coverage: 5,663 distinct patent families (13,038 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 12,402 (95%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
PARP1poly(ADP-ribose) polymerase 1Inhibition8.34.1%P09874
PARP2poly(ADP-ribose) polymerase 2Inhibition90.2%Q9UGN5
PARP3poly (ADP-ribose) polymerase 3Inhibition8.240.3%Q9Y6F1

Broader ChEMBL bioactivity targets: 19 (assay-derived). Sample: Protein mono-ADP-ribosyltransferase PARP14, Protein mono-ADP-ribosyltransferase PARP15, Adenosine receptor A1, Protein mono-ADP-ribosyltransferase PARP6, Protein mono-ADP-ribosyltransferase TIPARP, Protein mono-ADP-ribosyltransferase PARP11, cGMP-inhibited 3’,5’-cyclic phosphodiesterase 3A, Protein mono-ADP-ribosyltransferase PARP10, Protein mono-ADP-ribosyltransferase PARP12, Cyclin-dependent kinase 6.

Bioactivity

ChEMBL activities: 235 potent at pChembl ≥ 5 of 243 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
PARP210IC500.1nMCHEMBL_ACT_24870107
PARP110IC500.1nMCHEMBL_ACT_25997326
PARP29.96IC500.11nMCHEMBL_ACT_25997329
PARP29.89IC500.13nMCHEMBL_ACT_25647316
PARP19.62Kd0.24nMCHEMBL_ACT_15685813
PARP29.57Kd0.27nMCHEMBL_ACT_23310948
PARP29.55Kd0.28nMCHEMBL_ACT_15685823
PARP29.52IC500.3nMCHEMBL_ACT_25894464
PARP19.51Kd0.31nMCHEMBL_ACT_23310946
PARP29.4IC500.4nMCHEMBL_ACT_18847783
PARP19.4EC500.4nMCHEMBL_ACT_22440938
PARP29.4IC500.4nMCHEMBL_ACT_22440996
PARP19.4IC500.4nMCHEMBL_ACT_25894393
PARP19.39IC500.41nMCHEMBL_ACT_25490468
PARP29.35IC500.45nMCHEMBL_ACT_17739889
PARP29.3IC500.5nMCHEMBL_ACT_18847782
PARP29.3IC500.5nMCHEMBL_ACT_22432628
PARP29.3Kd0.5nMCHEMBL_ACT_24867469
PARP19.3IC500.5nMCHEMBL_ACT_25920766
PARP19.29IC500.51nMCHEMBL_ACT_25647313
PARP19.22IC500.6nMCHEMBL_ACT_24508658
PARP19.22IC500.6nMCHEMBL_ACT_24799427
PARP19.2IC500.63nMCHEMBL_ACT_24733579
PARP19.14IC500.73nMCHEMBL_ACT_24870079
PARP19.1Ki0.79nMCHEMBL_ACT_18881212
PARP19.1Kd0.8nMCHEMBL_ACT_24867463
PARP19.08IC500.83nMCHEMBL_ACT_25662290
PARP29.06IC500.87nMCHEMBL_ACT_25662292
PARP19.05IC500.9nMCHEMBL_ACT_17739888
PARP19.05IC500.9nMCHEMBL_ACT_22432610

Target pathways

Aggregated over 3 target gene(s): PARP1, PARP2, PARP3.

Top Reactome pathways

8 total, by targets touching each:

PathwayTargetsGenes
POLB-Dependent Long Patch Base Excision Repair2PARP1, PARP2
HDR through MMEJ (alt-NHEJ)2PARP1, PARP2
DNA Damage Recognition in GG-NER2PARP1, PARP2
Formation of Incision Complex in GG-NER2PARP1, PARP2
Dual Incision in GG-NER2PARP1, PARP2
vRNA Synthesis1PARP1
Downregulation of SMAD2/3:SMAD4 transcriptional activity1PARP1
SUMOylation of DNA damage response and repair proteins1PARP1

Dominant GO biological processes

GO termTargets
DNA repair3
double-strand break repair3
DNA damage response3
DNA ADP-ribosylation3
protein auto-ADP-ribosylation3
telomere maintenance2
decidualization2
protein poly-ADP-ribosylation2
protein localization to chromatin2
DNA repair-dependent chromatin remodeling2
protein localization to site of double-strand break2
negative regulation of transcription by RNA polymerase II1
transcription by RNA polymerase II1
apoptotic process1
mitochondrion organization1

Indications & clinical

Indications

77 indications (12 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
neoplasm4MONDO:0005070EFO:0000616
ovarian carcinoma4MONDO:0005140EFO:0001075
breast carcinoma4MONDO:0004989EFO:0000305
breast neoplasm4MONDO:0021100EFO:0003869
prostate carcinoma4MONDO:0005159EFO:0001663
exocrine pancreatic carcinoma4MONDO:0005192EFO:0002618
ovarian neoplasm4MONDO:0021068EFO:0003893
pancreatic neoplasm4MONDO:0021040EFO:0003860
ovarian cancer4MONDO:0008170MONDO:0008170
prostate adenocarcinoma3MONDO:0005082EFO:0000673
non-small cell lung carcinoma3MONDO:0005233EFO:0003060
carcinoma3MONDO:0004993EFO:0000313
metastatic prostate carcinoma3MONDO:0004956EFO:0000196
small cell lung carcinoma3MONDO:0008433EFO:0000702
endometrium neoplasm3MONDO:0021251EFO:0004230
endometrial carcinoma3MONDO:0002447EFO:1001512
gastric adenocarcinoma3MONDO:0005036EFO:0000503
gastric neoplasm3MONDO:0021085MONDO:0001056
lung neoplasm3MONDO:0021117MONDO:0008903
Ewing sarcoma2MONDO:0012817EFO:0000174
head and neck squamous cell carcinoma2MONDO:0010150EFO:0000181
germ cell tumor2MONDO:0005040EFO:0000514
sarcoma2MONDO:0005089EFO:0000691
glioblastoma2MONDO:0018177EFO:0000519
squamous cell carcinoma2MONDO:0005096EFO:0000707
urinary bladder neoplasm2MONDO:0004987EFO:0000294
mesothelioma2MONDO:0005065EFO:0000588
renal cell carcinoma2MONDO:0005086EFO:0000681
fallopian tube carcinoma2MONDO:0006206EFO:1000251
peritoneal neoplasm2MONDO:0006901EFO:1001100
angiosarcoma2MONDO:0016982EFO:0003968
cholangiocarcinoma2MONDO:0019087EFO:0005221
soft tissue sarcoma2MONDO:0018078EFO:1001968
fallopian tube neoplasm2MONDO:0021092MONDO:0002158
bile duct neoplasm2MONDO:0021662MONDO:0003059
osteosarcoma2MONDO:0009807EFO:0000637
cervical carcinoma2MONDO:0005131EFO:0001061
metastatic melanoma2MONDO:0005191EFO:0002617
triple-negative breast carcinoma2MONDO:0005494EFO:0005537
glioma2MONDO:0021042MONDO:0100342
carcinosarcoma2MONDO:0002928MONDO:0002928
myelodysplastic syndrome2MONDO:0018881EFO:0000198
peripheral T-cell lymphoma, not otherwise specified2MONDO:0004964EFO:0000211
acute myeloid leukemia2MONDO:0018874EFO:0000222
adrenal gland pheochromocytoma2MONDO:0004974EFO:0000239
leiomyosarcoma2MONDO:0005058EFO:0000564
melanoma2MONDO:0005105EFO:0000756
uveal melanoma2MONDO:0006486EFO:1000616
myeloid leukemia2MONDO:0004643MONDO:0004643
pancreatic ductal adenocarcinoma2MONDO:0005184MONDO:0005184
colorectal neoplasm2MONDO:0005335MONDO:0005575
lymphoma1MONDO:0005062EFO:0000574
pulmonary arterial hypertension1MONDO:0015924EFO:0001361
head and neck cancer1MONDO:0005627EFO:0006859
inflammatory breast carcinoma1MONDO:0006804EFO:1000984
hereditary breast ovarian cancer syndrome1MONDO:0003582Orphanet:145
rhabdomyosarcoma1MONDO:0005212EFO:0002918
central nervous system neoplasm1MONDO:0006130EFO:1000158
neuroendocrine neoplasm1MONDO:0019496EFO:1001901
uterine cancer1MONDO:0002715MONDO:0002715
B-cell chronic lymphocytic leukemia1MONDO:0004948EFO:0000095
serous adenocarcinoma1MONDO:0005278EFO:0003825
oral cavity squamous cell carcinoma1MONDO:0004958EFO:0000199
carcinoma of esophagus1MONDO:0019086EFO:0002916
tumor of uterus1MONDO:0021353EFO:0003859

12 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 383.

Phase distribution

PhaseTrials
PHASE2197
PHASE187
PHASE1/PHASE236
PHASE332
Not specified11
EARLY_PHASE110
PHASE46
PHASE2/PHASE34

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05078671PHASE4RECRUITINGPharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness
NCT05457257PHASE4ACTIVE_NOT_RECRUITINGClinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
NCT06121401PHASE4ACTIVE_NOT_RECRUITINGFirst Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients
NCT02476968PHASE4COMPLETEDTo Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer
NCT04330040PHASE4COMPLETEDProspective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer
NCT05949424PHASE4UNKNOWNOPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
NCT02032823PHASE3ACTIVE_NOT_RECRUITINGOlaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
NCT02446600PHASE3ACTIVE_NOT_RECRUITINGTesting the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02502266PHASE2/PHASE3ACTIVE_NOT_RECRUITINGTesting the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
NCT03150576PHASE2/PHASE3RECRUITINGPlatinum and Polyadenosine 5’Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer
NCT03486873PHASE3RECRUITINGLong-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT03732820PHASE3ACTIVE_NOT_RECRUITINGStudy on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
NCT03737643PHASE3ACTIVE_NOT_RECRUITINGDurvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
NCT04269200PHASE3ACTIVE_NOT_RECRUITINGDurvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
NCT04380636PHASE3ACTIVE_NOT_RECRUITINGStudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
NCT04421963PHASE3ACTIVE_NOT_RECRUITINGRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
NCT04884360PHASE3ACTIVE_NOT_RECRUITINGD9319C00001- 1L OC Mono Global RCT
NCT05171816PHASE3ACTIVE_NOT_RECRUITINGStudy on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)
NCT05255471PHASE3RECRUITINGMITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.
NCT05255653PHASE2/PHASE3RECRUITINGRefining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features
NCT05432791PHASE2/PHASE3ACTIVE_NOT_RECRUITINGTesting Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working
NCT06112379PHASE3ACTIVE_NOT_RECRUITINGA Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06580314PHASE3RECRUITINGTesting Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT06915025PHASE3RECRUITINGPhase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
NCT06966700PHASE3RECRUITINGA Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT01924533PHASE3COMPLETEDEfficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
NCT02000622PHASE3COMPLETEDAssessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.
NCT02184195PHASE3COMPLETEDOlaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
NCT02282020PHASE3COMPLETEDOlaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments
NCT02392676PHASE3WITHDRAWNOlaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations
NCT02477644PHASE3COMPLETEDPlatine, Avastin and OLAparib in 1st Line
NCT02987543PHASE3COMPLETEDStudy of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)
NCT03278717PHASE3UNKNOWNStudy Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients
NCT03286842PHASE3COMPLETEDTo Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
NCT03402841PHASE3COMPLETEDMulticentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients
NCT03740165PHASE3COMPLETEDStudy of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
NCT03784014PHASE3COMPLETEDMolecular Profiling of Advanced Soft-tissue Sarcomas
NCT03834519PHASE3COMPLETEDStudy of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)
NCT03976323PHASE3COMPLETEDStudy of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
NCT03976362PHASE3COMPLETEDA Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)

Clinical evidence (CIViC)

Variant × indication × effect (91 predictive associations from 105 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
BRCA1 MutationProstate CancerSensitivity/ResponseOlaparibCIViC AEID12943 +2
BRCA1 MutationOvarian CancerSensitivity/ResponseOlaparibCIViC AEID7274 +2
BRCA2 MutationOvarian CancerSensitivity/ResponseOlaparibCIViC AEID7276 +2
BRCA2 MutationProstate CancerSensitivity/ResponseOlaparibCIViC AEID12942 +2
BRCA1 Loss-of-functionHer2-receptor Negative Breast CancerSensitivity/ResponseOlaparibCIViC AEID11201 +1
BRCA2 Loss-of-functionHer2-receptor Negative Breast CancerSensitivity/ResponseOlaparibCIViC AEID11202 +1
ATM MutationCastration-resistant Prostate CarcinomaSensitivity/ResponseOlaparibCIViC AEID8505
BARD1 MutationCastration-resistant Prostate CarcinomaSensitivity/ResponseOlaparibCIViC AEID11209
BRCA1 Loss-of-functionTriple-receptor Negative Breast CancerSensitivity/ResponseOlaparibCIViC AEID11216
BRCA1 Loss-of-functionPancreatic AdenocarcinomaSensitivity/ResponseOlaparibCIViC AEID7384
BRCA1 MutationCastration-resistant Prostate CarcinomaSensitivity/ResponseOlaparibCIViC AEID11203
BRCA1 Mutation AND BRCA2 MutationProstate CancerSensitivity/ResponseOlaparibCIViC AEID12941
BRCA2 Loss-of-functionTriple-receptor Negative Breast CancerSensitivity/ResponseOlaparibCIViC AEID11217
BRCA2 Loss-of-functionPancreatic AdenocarcinomaSensitivity/ResponseOlaparibCIViC AEID7385
BRCA2 MutationCastration-resistant Prostate CarcinomaSensitivity/ResponseOlaparibCIViC AEID8842
BRIP1 MutationCastration-resistant Prostate CarcinomaSensitivity/ResponseOlaparibCIViC AEID11208
CDK12 MutationCastration-resistant Prostate CarcinomaSensitivity/ResponseOlaparibCIViC AEID11204
CHEK1 MutationCastration-resistant Prostate CarcinomaSensitivity/ResponseOlaparibCIViC AEID11210
CHEK2 mutationCastration-resistant Prostate CarcinomaSensitivity/ResponseOlaparibCIViC AEID11205
FANCL MutationCastration-resistant Prostate CarcinomaSensitivity/ResponseOlaparibCIViC AEID11211
PALB2 MutationCastration-resistant Prostate CarcinomaSensitivity/ResponseOlaparibCIViC AEID8504
RAD51B MutationCastration-resistant Prostate CarcinomaSensitivity/ResponseOlaparibCIViC AEID11212
RAD51C MutationCastration-resistant Prostate CarcinomaSensitivity/ResponseOlaparibCIViC AEID11213
RAD51D MutationCastration-resistant Prostate CarcinomaSensitivity/ResponseOlaparibCIViC AEID11214
RAD54L MutationCastration-resistant Prostate CarcinomaSensitivity/ResponseOlaparibCIViC AEID11207
ATM MutationProstate CancerSensitivity/ResponseOlaparibCIViC BEID7458 +2
ATM UnderexpressionStomach CancerSensitivity/ResponsePaclitaxel + OlaparibCIViC BEID5215 +1
BAP1 MutationMalignant MesotheliomaSensitivity/ResponseOlaparibCIViC BEID11740 +1
BRCA1 Loss-of-functionOvarian CancerSensitivity/ResponseOlaparibCIViC BEID211
BRCA1 MutationCancerSensitivity/ResponseOlaparibCIViC BEID1370

+61 more predictive associations (showing top 30 by level).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

54 molecules share ≥1 primary target. Top 54 by shared-target count:

MoleculeSourceStatusShared targets
NIRAPARIBChEMBL + PubChemPhase 4 (approved)PARP1, PARP2, PARP3
RUCAPARIBChEMBL + PubChemPhase 4 (approved)PARP1, PARP2, PARP3
TALAZOPARIBChEMBL + PubChemPhase 4 (approved)PARP1, PARP2, PARP3
PAMIPARIBChEMBLPhase 3PARP1, PARP2, PARP3
SARUPARIBChEMBLPhase 3PARP1, PARP2, PARP3
VELIPARIBChEMBLPhase 3PARP1, PARP2, PARP3
2X-121ChEMBLPhase 2PARP1, PARP2
AMITRIPTYLINEChEMBLPhase 4 (approved)PARP1
PALBOCICLIBChEMBLPhase 4 (approved)PARP1
RUCAPARIB CAMSYLATEChEMBLPhase 4 (approved)PARP1
FLUZOPARIBChEMBLPhase 3PARP1
INIPARIBChEMBLPhase 3PARP1
AMELPARIBChEMBLPhase 2PARP1
CHLORTHENOXAZINEChEMBLPhase 2PARP1
E-7016ChEMBLPhase 2PARP1
FLAVONEChEMBLPhase 2PARP1
LUTEOLINChEMBLPhase 2PARP1
NESUPARIBChEMBLPhase 2PARP1
AfatinibPubChemApprovedPARP1
ApixabanPubChemApprovedPARP1
belumosudilPubChemApprovedPARP1
BinimetinibPubChemApprovedPARP1
CarfilzomibPubChemApprovedPARP1
chenodiolPubChemApprovedPARP1
ClascoteronePubChemApprovedPARP1
ClofarabinePubChemApprovedPARP1
CrizotinibPubChemApprovedPARP1
cytisiniclinePubChemApprovedPARP1
dacomitinibPubChemApprovedPARP1
ElagolixPubChemApprovedPARP1
EribulinPubChemApprovedPARP1
FingolimodPubChemApprovedPARP1
IdelalisibPubChemApprovedPARP1
LactulosePubChemApprovedPARP1
LinagliptinPubChemApprovedPARP1
MavacamtenPubChemApprovedPARP1
MegestrolPubChemApprovedPARP1
NitisinonePubChemApprovedPARP1
PazopanibPubChemApprovedPARP1
podofiloxPubChemApprovedPARP1
PramipexolePubChemApprovedPARP1
PyrazinamidePubChemApprovedPARP1
regorafenibPubChemApprovedPARP1
RelugolixPubChemApprovedPARP1
RiociguatPubChemApprovedPARP1
RitlecitinibPubChemApprovedPARP1
RolapitantPubChemApprovedPARP1
saxagliptinPubChemApprovedPARP1
SelumetinibPubChemApprovedPARP1
TadalafilPubChemApprovedPARP1
TaurinePubChemApprovedPARP1
TrabectedinPubChemApprovedPARP1
TrametinibPubChemApprovedPARP1
VorapaxarPubChemApprovedPARP1

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot